Ancora Heart
Santa Clara, US · Delaware corporation
Ancora Heart develops minimally invasive medical devices, including a class III implantable therapy for cardiovascular treatment. The company focuses on cardiac/heart failure therapy development, clinical research, and commercialization of its core technology.
HealthtechMedical Devices
Founders & leadership
DC
David C. AuthNamed on SEC filing
RW
Robert W. CroceNamed on SEC filing
JC
Jeffrey ClossNamed on SEC filing
LC
Lewis C. PellNamed on SEC filing
AM
Andrew MidlerNamed on SEC filing
JM
Jeffrey M. ClossPresident & CEO
RS
Russel SampsonChief Technical Officer
MM
Mark MilesChief Commercial Officer
Reported raises · per SEC filings
Form D private placements$121.3M disclosed across 3 rounds · 2018–2021
▶$80MraisedJul 2021 · 47 investors · Other Health CareRule 506(b)
▶$80MraisedJul 2021 · 47 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Lewis C. PellDirector
- Jeffrey ClossExecutive Officer, Director
- Robert W. CroceDirector
- Andrew MidlerDirector
- Beverly A. HussDirector
- David C. AuthDirector
- Offering amount
- $80M
- Amount sold
- $80M
- First sale
- Jun 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$23.5MraisedDec 2018 · 5 investors · Other Health CareRule 506(b)
▶$23.5MraisedDec 2018 · 5 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Robert W. CroceDirector
- Andrew MidlerDirector
- David C. AuthDirector
- Jeffrey ClossExecutive Officer, Director
- Lewis C. PellDirector
- Offering amount
- $35M
- Amount sold
- $23.5M
- First sale
- Dec 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$17.8MraisedMay 2018 · 32 investors · Other Health CareRule 506(b)
▶$17.8MraisedMay 2018 · 32 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- David C. AuthDirector
- Robert W. CroceDirector
- Jeffrey ClossExecutive Officer, Director
- Lewis C. PellDirector
- Andrew MidlerDirector
- Offering amount
- $30M
- Amount sold
- $17.8M
- First sale
- May 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlapMassdevice25 shared keywordsMassDevice is a news and media outlet covering the medical device industry, publishing articles, special reports, and white papers on medtech companies, products, and regulatory topics such as FDA 510(k) submissions. It serves medical device professionals with industry news and analysis.
Rf Surgical14 shared keywordsMedtronic is a healthcare technology company that develops medical devices and technologies — including pacemakers, robotic-assisted surgery systems, and AI-driven health tools — used by doctors, scientists, and engineers to treat pain and disease. It works with clinicians to create solutions aimed at treating conditions such as AFib.
Bioworld13 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies competing with Ancora Heart for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Ancora Heart do?
- Ancora Heart develops minimally invasive medical devices, including a class III implantable therapy for cardiovascular treatment. The company focuses on cardiac/heart failure therapy development, clinical research, and commercialization of its core technology.
- How much funding has Ancora Heart raised?
- Ancora Heart has disclosed $121.3M raised across 3 rounds.
- Where is Ancora Heart headquartered?
- Ancora Heart is headquartered in Santa Clara, US.